ABBV vs MYNZ

AbbVie Inc. (ABBV) is a well-established mega-cap pharmaceutical company with a robust product portfolio, strong financial health, and a leading position in key therapeutic areas. It excels as a stable dividend payer and a defensive holding. However, its fundamental characteristics, including its immense market capitalization ($397.29B), the mature nature of the pharmaceutical industry, high R&D c...

MYNZ presents an exceptionally high-risk, ultra-speculative scenario, even more so than previously assessed. The company has undergone a complete pivot, discontinuing its colorectal cancer screening business (ColoAlert IP is being sold) and shifting entirely to post-quantum cybersecurity (Quantum Cyber brand). This pivot is accompanied by a severe recapitalization event where existing shareholders...